Jiuzhou Pharma (603456.SS) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Jiuzhou Pharma is a full-service CDMO that has successfully evolved from a generic API manufacturer into a strategic partner for innovative drug development. Its strategy is built on deep process innovation, a comprehensive portfolio of specialized technology platforms (including chiral catalysis, continuous flow, and peptide synthesis), and a commitment to green chemistry. The company serves over 900 global partners, including major pharmaceutical firms, and supports drug programs from early clinical phases to commercial supply, aiming to accelerate the time-to-market for novel therapeutics.

Small MoleculesDrug Delivery

Technology Platform

A diversified portfolio of proprietary platforms for small molecule (chiral catalysis, continuous flow, fluorine chemistry), drug product (solubility enhancement, controlled release), and peptide (synthesis, conjugates) development and manufacturing, underpinned by a commitment to green chemistry.

Opportunities

Capitalizing on the global trend of pharmaceutical outsourcing, especially from virtual biotechs and big pharma seeking high-quality, cost-effective partners in China.

Growing demand for complex chemistry (peptides, chiral molecules) and green manufacturing technologies aligns perfectly with the company's core platforms.

Risk Factors

Exposure to geopolitical tensions between China and Western markets, intense competition from global and domestic CDMOs, and operational risks related to client program failures or quality/compliance issues at manufacturing sites.

Competitive Landscape

Competes with global CDMO giants (Lonza, Catalent, Cambrex) and leading Chinese peers (WuXi AppTec, Pharmaron). Differentiates through deep, integrated small molecule and peptide technology platforms, a full lifecycle service model, and a strong track record in API manufacturing scaled from its generic origins.

More companies in Small Molecule Drugs →More companies in Germany →